CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
ADVOS is developing a unique device that simultaneously supports the liver, lungs, kidneys, and acid-base balance in intensive care patients suffering from multiple organ failure. This low-invasive technology aims to significantly improve survival rates and reduce complications associated with organ failure treatments.
60% of intensive care patients die of multiple organ failure (MOF), resulting in a market potential in Western EU of €1.19bn in 13 targeted countries and in the US of €2.05bn.
The detoxification organs are nearly always involved in MOF.
Therefore, to treat MOF successfully, the vicious cycle of progressing organ failures and increasing toxin accumulation in the body has to be stopped. ADVOS has the potential to revolutionize the therapy of ICU patients worldwide, as it is the first and only ICU…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
